C-CJQT

FILE C-CJQT·COMPANY·CURATED BY ETERNAL SEARCH

MAIA

telomere targeting, immuno-oncology, small molecule

modulatingsmall molecule

maiabiotech.com·Chicago, Illinois, United States·Founded 2018·Public·$37M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-CJQT

Projects

Ateganosine in advanced/metastatic NSCLC

phase 3

drug program · high · Mon Dec 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Treat advanced or metastatic non-small cell lung cancer by targeting telomerase-positive cancer cells and restoring or enhancing response to PD-1 immunotherapy after prior immune checkpoint inhibitor exposure.

Small-molecule telomere-targeting agent administered before cemiplimab, a PD-1 inhibitor; evaluated against chemotherapy as third-line treatment in advanced/metastatic NSCLC.

Phase III study of THIO plus cemiplimab versus chemotherapy as third-line treatment in advanced/metastatic NSCLC.

Second-generation telomere-targeting agent MAIA-2021-029

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.

Second-generation telomere-targeting agent MAIA-2021-20

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.

Second-generation telomere-targeting agent MAIA-2022-12

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

Ateganosine in advanced/metastatic NSCLC

phase 3

drug program · high · Mon Dec 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Small-molecule telomere-targeting agent administered before cemiplimab, a PD-1 inhibitor; evaluated against chemotherapy as third-line treatment in advanced/metastatic NSCLC.

Phase III study of THIO plus cemiplimab versus chemotherapy as third-line treatment in advanced/metastatic NSCLC.

Second-generation telomere-targeting agent MAIA-2021-029

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.

Second-generation telomere-targeting agent MAIA-2021-20

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.

Second-generation telomere-targeting agent MAIA-2022-12

undisclosed

drug program · medium · Thu Jan 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop a second-generation telomere-targeting therapy for telomerase-positive cancers.

Telomere-targeting small-molecule/dinucleotide therapeutic approach intended for cancer treatment.

Identified by the company as a second-generation telomere-targeting agent; related MAIA patent publication covers dinucleotides and their use in cancer treatment.